27 March 2024 | News
Adds capabilities of late-stage clinical trial execution with strong focus on oncology
image credit- shutterstock
Veeda Clinical Research, Ahmedabad-based full-service contract research organisation (CRO), has acquired Heads, a privately held European CRO, which specialises in conducting clinical trials in oncology.
Established in 2010, Heads has operational presence in 25 multiple strategically important locations across Europe, North America and Asia Pacific region. Through this acquisition, Veeda enters the league of global CROs with integrated capabilities to extend contract research services from discovery to clinical development extending to post commercial launch.
The acquisition provides Heads a strong operational platform and an opportunity to expand its expertise and capabilities to the Indian and South-East Asian markets. India's diverse demographic profile provides a unique opportunity to conduct clinical trials, especially in therapeutic areas including oncology, diabetes, hypertension, infectious diseases, and special diseases.
With this acquisition, Veeda’s global pharmaceutical and biotech clients can now leverage the unique and unparalleled suite of early to late-phase CRO services across Europe, US, and Asia Pacific. Veeda’s ever-growing relationship with large biopharma companies and access to key opinion leaders (KOLs) across multiple countries will accelerate execution of global clinical trials in both the western and eastern populations.